The molecular targets of approved treatments for pulmonary arterial hypertension

Marc Humbert,1,2,3 Hossein-Ardestich Ghofrani4,5

ABSTRACT

Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an additional drug class has become available targeting a distinct molecular target in the same pathway as PDE5 inhibitors. Treatment recommendations currently include the use of all four drug classes to treat PAH, but there is a lack of comparative data for these therapies. Therefore, an understanding of the mechanistic differences between these agents is critical when making treatment decisions. Combination therapy is often used to treat PAH and it is therefore important that physicians understand how the modes of action of these drugs may interact to work as complementary partners, or potentially with unwanted consequences. Furthermore, different patient phenotypes mean that patients respond differently to treatment; while a certain monotherapy may be adequate for some patients, for others it will be important to consider alternating or combining compounds with different molecular targets. This review describes how the four currently approved drug classes target the complex pathobiology of PAH and will consider the distinct target molecules of each drug class, their modes of action, and review the pivotal clinical trial data supporting their use. It will also discuss the rationale for combining drugs (or not) from the different classes, and review the clinical data from studies on combination therapy.

BACKGROUND

Pulmonary arterial hypertension (PAH) is a chronic, potentially fatal disease characterised haemodynamically by increased mean pulmonary artery pressure ≥25 mm Hg, normal pulmonary artery wedge pressure ≤15 mm Hg and elevated pulmonary vascular resistance (PVR) >3 Wood Units. PAH is caused by progressive remodelling of the pulmonary vasculature by cell proliferation and fibrosis, occluding the blood vessels and ultimately leading to right ventricular failure and death.1–3 The vascular pathology of PAH results at least in part from endothelial cell dysfunction, accompanied by impaired signalling in several pathways.4–9 Despite advances in current therapies for PAH, there is still a significant unmet medical need, as the mortality of patients with PAH remains high.10–12

Until recently, three classes of medical therapy were available for the treatment of PAH targeting three dysfunctional pathways—prostanoids, endothelin receptor antagonists (ERAs) and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase (sGC) stimulator riociguat,13–16 a new, fourth class of therapy has become available, targeting the same pathway as PDE5 inhibitors. The treatment algorithm discussed at the 5th World Symposium on Pulmonary Hypertension (PH)17 recommends the use of all four drug classes to treat PAH (table 1), as do the recently published CHEST guidelines on pharmacological therapy for PAH in adults (table 2).18 However, there is a lack of comparative data for these therapies; therefore, an understanding of the mechanistic differences between these agents and the clinical data sets supporting their use is critical when making treatment decisions.

Inter-individual differences mean that patients can respond differently to the same PAH treatment. Monotherapy may be adequate for some patients, while others may only improve when treated with a combination of two or three different classes of drugs. Although it is unclear whether these patients are benefiting from combination therapy, or whether the use of more than one drug is increasing the patient’s chances of receiving the treatment to which they are most responsive, for patients who receive combination therapy, it is important to consider alternating or combining compounds with different molecular targets. Combination therapy is often used to treat PAH and it is important, therefore, that physicians understand how the modes of action of these drugs might result in additive, synergistic or antagonistic interactions which could lead to differences in safety and efficacy.

This review will give a comprehensive overview of the available approved medical treatments for PAH, describing how each drug class targets the complex pathobiology of PAH, and will consider the distinct target molecules of each drug class. We will also discuss the rationale for combination therapy and review the clinical evidence for the use of combination therapy.

Currently approved therapies and their molecular targets

The modes of action of the approved classes of therapy for PAH are illustrated in figure 1. Key positive clinical trial data for each therapy are summarised in tables 3 and 4.

Prostanoids: stimulation of adenylyl cyclase through prostacyclin (IP) receptor agonism

Prostaglandin I2 (PGI2) or prostacyclin is a potent pulmonary vasodilator synthesised in the endothelium.16 Its main target, the IP receptor, is expressed in the vascular smooth muscle cell (VSMC) layer of the pulmonary vasculature17–19 as well as other tissues. Activation of the IP receptor results in the conversion of ATP to cyclic AMP (cAMP) which
increases protein kinase A (PKA) activity, leading to downstream effects including vasodilation. Prostacyclin has antithrombotic, antiproliferative, antimitogenic and immunomodulatory properties.\textsuperscript{38–42} Prostacyclin synthase and prostacyclin metabolites are reduced in the pulmonary vasculature and blood serum of patients with PH.\textsuperscript{43,44} The prostanoid drugs are synthetic analogues of prostacyclin, designed to substitute the endogenous prostacyclin that is lacking in these patients.

**Table 2** Summary of CHEST/American College of Chest Physicians guidelines for pharmacological treatment of PAH\textsuperscript{18}

<table>
<thead>
<tr>
<th>Patient status*</th>
<th>WHO FC II</th>
<th>WHO FC III</th>
<th>WHO FC IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment naïve</td>
<td>Monotherapy with any approved ERA, PDE5i or riociguat</td>
<td>Monotherapy with any approved ERA, PDE5i or riociguat</td>
<td>Monotherapy with parenteral prostanoid plus inhaled prostanoid</td>
</tr>
<tr>
<td>Treatment naïve, unable or unwilling to receive parenteral prostanoids</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Treatment naïve with evidence of rapid disease progression or markers of poor prognosis</td>
<td>–</td>
<td>Initial monotherapy with parenteral prostanoid or subcutaneous treprostinil</td>
<td>–</td>
</tr>
<tr>
<td>Receiving one or two oral therapies with evidence of rapid disease progression or markers of poor prognosis</td>
<td>–</td>
<td>Addition of parenteral or inhaled prostanoid</td>
<td>–</td>
</tr>
<tr>
<td>Receiving ERA or PDE5i but remains symptomatic</td>
<td>–</td>
<td>Addition of inhaled prostanoid</td>
<td>–</td>
</tr>
<tr>
<td>Receiving established monotherapy, with unacceptable clinical status</td>
<td>–</td>
<td>Add inhaled prostanoids to stable ERA/PDE5i</td>
<td>–</td>
</tr>
<tr>
<td>Receiving dual combined therapy, with unacceptable clinical status</td>
<td>–</td>
<td>Add sildenafil to epoprostenol</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Add macitentan to PDE5i</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Add a third class of therapy. Patient should ideally be treated at an expert centre</td>
<td>–</td>
</tr>
</tbody>
</table>

\*Pharmacotherapy is not recommended for patients with WHO FC I.

Epoprostenol
Epoprostenol is a synthetic salt of PGI\textsubscript{2}, and was the first prostanoid to be tested in patients with PAH.\textsuperscript{19} It is approved in the USA, Europe and several other regions for treatment of PAH in patients in WHO functional class (WHO FC) III and IV, who do not respond adequately to conventional therapy. Epoprostenol is unstable, with a half-life of \(<5\) min, and is administered intravenously via an indwelling central venous catheter connected to

---

**Table 1** Treatment recommendations from the 5th World Symposium on Pulmonary Hypertension\textsuperscript{17}

<table>
<thead>
<tr>
<th>Initial therapy with PAH approved drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Reprinted with permission from Elsevier.

Level definition:
A: Data derived from multiple randomised clinical trials or meta-analyses.
B: Data derived from a single randomised clinical trial or large non-randomised studies.
C: Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

Results on the basis of post-hoc and subgroup analyses of clinical trials most often do not meet the criteria of a level of evidence A.

Classes of recommendations.
Class I: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Is recommended, is indicated.
Class II: Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.
Class IIa: Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered.
Class IIb: Usefulness/efficacy is less well established by evidence/opinion. May be considered.
Class III: Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful. Is not recommended.

\*Level of evidence is based on the WHO FC of the majority of patients in the studies.

\textsuperscript{†}Approved only: by the FDA (treprostinil inhaled); in New Zealand (iloprost intravenous); in Japan and South Korea (beraprost).

FDA, US Food and Drug Administration; PAH, pulmonary arterial hypertension; WHO FC, WHO functional class.
an infusion pump. As such, meticulous hygiene must be observed due to the risk of catheter site infection. Interruption of drug supply can result in severe and potentially fatal rebound PH. In 2008, a novel formulation was introduced (Veletri, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) that is stable at room temperature for up to 24 h, eliminating the need for ice packs to cool the pump. Details of the randomised trial of epoprostenol are listed in Table 3.

Iloprost
Iloprost is a carbacyclin analogue of PGI$_2$ that has improved stability at room temperature and a longer half-life (20–30 min) compared with epoprostenol. It can be administered intravenously or by inhalation. Inhaled iloprost is approved in the USA for patients with PAH in WHO FC II or III, and in Europe and several other countries for patients with PAH in WHO FC III. Details of the AIR study of inhaled iloprost are listed in Table 3. Intravenous iloprost treatment has been evaluated in several open-label uncontrolled clinical studies, however not in a randomised controlled clinical trial, and is only approved in New Zealand for PAH.

Beraprost
Beraprost is a prostanoid with a half-life of 35–40 min that is administered orally. Although treatment with beraprost initially improved 6 min walking distance (6MWD) (ALPHABET study, table 3), long-term follow-up showed that the improvement was not sustained. Beraprost is approved in Japan, South Korea and some other South-East Asian countries such as Indonesia for treatment of PAH in patients in WHO FC III.

Trexprostinil
Trexprostinil is an analogue of PGI$_2$ which has a longer half-life (up to 4 h) and improved stability compared with epoprostenol. It can be administered via subcutaneous, intravenous, inhaled and oral routes. Subcutaneous treprostinil is approved in the USA for the treatment of patients with PAH in WHO FC II–IV, and in Europe for patients with PAH in WHO FC III. Intravenous treprostinil should be reserved for patients who are intolerant of the subcutaneous route, patients with a preference for intravenous administration, or in whom the risks are considered warranted. Inhaled and oral treprostinil are only approved in the USA, and oral treprostinil is only approved in treatment-naïve patients with PAH, whereas inhaled treprostinil is only approved for use in combination therapy. Details of the randomised trials of subcutaneous, inhaled (TRIUMPH I) and oral treprostinil (FREEDOM-M) are listed in Table 3.

Selexipag
Selexipag is a selective, non-prostanoid IP receptor agonist. It is rapidly metabolised to an active form with a half-life of 7.9 h,
<table>
<thead>
<tr>
<th>Trial name</th>
<th>Treatment</th>
<th>Trial duration</th>
<th>Number/type of patients</th>
<th>Primary endpoint met</th>
<th>Secondary endpoint significant improvements</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of primary PH with continuous intravenous prostacyclin</td>
<td>Continuous intravenous epoprostenol at doses determined during baseline</td>
<td>8 weeks</td>
<td>19 patients with primary PH, 10 patients received epoprostenol and 9 received only</td>
<td>Total pulmonary resistance −7.9 units (95% CI −13.1 to −2.2) at 8 weeks, sustained</td>
<td>Mean PAP</td>
<td>Complications attributable to administration method</td>
</tr>
<tr>
<td>(epoprostenol)</td>
<td>catheterisation or conventional treatment (mean dose 7.9±2.7 ng/kg/min)</td>
<td></td>
<td>anticoagulants, oral vasodilators and diuretics</td>
<td>for up to 18 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue,</td>
<td>Continuous, subcutaneously infused treprostinil up to 22.5 ng/kg/min</td>
<td>12 weeks</td>
<td>470 patients with PH, either primary or associated with CTD or congenital systemic-to-pulmonary shunts</td>
<td>Change from baseline in 6MWD at 12 weeks. Median treatment difference +16 m (95% CI 4.4 to 27.6)</td>
<td>Haemodynamics, symptoms score, QoL</td>
<td>Infusion-site pain, infusion-site reaction, infusion-site bleeding, headache, diarrhoea, nausea, jaw pain, flushing, lower limb oedema, gastrointestinal haemorrhage</td>
</tr>
<tr>
<td>in patients with pulmonary arterial hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(TRIUMPH-I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-blind placebo-controlled clinical investigation into the efficacy</td>
<td>Inhaled treprostinil (up to 54 μg) four times daily</td>
<td>12 weeks</td>
<td>235 patients with PAH</td>
<td>Peak change from baseline in 6MWD at 12 weeks. Median treatment difference +20 m (95% CI 8.0 to 32.8)</td>
<td>QoL, NT-proBNP</td>
<td>Cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, diarrhoea</td>
</tr>
<tr>
<td>and tolerability of inhaled treprostinil sodium in patients with severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pulmonary arterial hypertension (TRIUMPH-II)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy and safety of oral treprostinil monotherapy for the treatment of</td>
<td>Oral treprostinil 0.25–12 mg twice daily</td>
<td>12 weeks</td>
<td>349 treatment-naive patients with PAH</td>
<td>Change from baseline in 6MWD at 12 weeks. Median treatment difference +23 m (95% CI 4 to 41)</td>
<td>Borg dyspnoea score</td>
<td>Headache, nausea, diarrhoea, jaw pain</td>
</tr>
<tr>
<td>pulmonary arterial hypertension (FREEDOM-M)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The aerosolised iloprost randomised study (AIR)</td>
<td>Inhaled iloprost 2.5 μg or 5 μg six or nine times daily; median inhaled</td>
<td>12 weeks</td>
<td>203 patients with mixed types of PH</td>
<td>An increase of at least 10% in 6MWD and 1 NYHA FC at 12 weeks. 16.8% of iloprost patients vs 4.9% of placebo patients achieved the primary endpoint</td>
<td>Haemodynamics, Borg dyspnoea score, QoL</td>
<td>Increased cough, flushing, jaw pain</td>
</tr>
<tr>
<td></td>
<td>dose 30 μg per day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial PH and beraprost European trial (ALPHABET)</td>
<td>Beraprost sodium 20–120 μg four times daily</td>
<td>12 weeks</td>
<td>130 patients with PAH</td>
<td>Change from baseline in 6MWD at 12 weeks. Mean treatment difference +25.1 m (95% CI 1.8 to 48.3)</td>
<td>Borg dyspnoea score</td>
<td>Headache, flushing, jaw pain, diarrhoea</td>
</tr>
<tr>
<td>Bosentan randomised trial of endothelin antagonist therapy (BREATHE-1)</td>
<td>Bosentan 62.5 mg three times daily for 4 weeks, increased to 125 or 250 mg</td>
<td>16 weeks</td>
<td>213 treatment-naive patients with either IPAH or PAH-CTD</td>
<td>Change from baseline in 6MWD at 12 weeks. Mean treatment difference +44 m (95% CI 21 to 67)</td>
<td>WHO FC, Borg dyspnoea score, TTCW</td>
<td>Headache, dizziness, worsening PAH</td>
</tr>
<tr>
<td>Endothelin antagonist trial in mildly symptomatic pulmonary arterial</td>
<td>Bosentan 62.5 mg three times daily, increasing to 125 mg three times daily</td>
<td>6 months</td>
<td>185 patients with WHO FC II PAH</td>
<td>PVR at rest at 6 months, expressed as a percentage of the baseline value and change from baseline in 6MWD at 6 months. Treatment difference −22.6% (95% CI −33.5 to −10.0) for PVR, and +19.1 m (95% CI 3.6 to 41.8) for 6MWD. 6MWD endpoint not significant</td>
<td>TTCW, NT-proBNP, QoL</td>
<td>Nasopharyngitis, abnormal liver function tests</td>
</tr>
<tr>
<td>hypertension patients (EARLY)</td>
<td>after 4 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Trial name</th>
<th>Treatment</th>
<th>Trial duration</th>
<th>Number/type of patients</th>
<th>Primary endpoint met</th>
<th>Secondary endpoint significant improvements</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlled, multicentre, efficacy (ARIES-1 and ARIES-2)</td>
<td>Ambrisentan ARIES-1, 5 or 10 mg once daily; ARIES-2, 2.5 or 5 mg once daily</td>
<td>12 weeks</td>
<td>202 (ARIES-1) and 192 (ARIES-2) patients with PAH</td>
<td>Change from baseline in 6MWD at week 12. Mean treatment difference +45 m (95% CI 24 to 65) for 5 mg combined; +32 m (95% CI 2 to 63) for 2.5 mg and +51 m (95% CI 27 to 76) for 10 mg</td>
<td>ARIES-1: WHO FC, Borg dyspnoea score, BNP, ARIES-2: TTCW, QoL, Borg dyspnoea score, BNP</td>
<td>Peripheral oedema, headache, nasal congestion</td>
</tr>
<tr>
<td>Study with an endothelin receptor antagonist in pulmonary arterial hypertension to improve clinical outcome (SERAPHIN)</td>
<td>Macitentan 3 mg or 10 mg once daily</td>
<td>Event-driven study, median duration 115 weeks</td>
<td>742 treatment-naive or pretreated patients with PAH</td>
<td>Time from initiation of treatment to first occurrence of a composite morbidity or mortality endpoint. HR vs placebo 0.7 (97.5% CI 0.52 to 0.96) for 3 mg; 0.55 (97.5% CI 0.39 to 0.76) for 10 mg</td>
<td>6MWD, WHO FC, haemodynamics</td>
<td>Headache, nasopharyngitis, anaemia</td>
</tr>
<tr>
<td>Sildenafil use in pulmonary arterial hypertension (SUPER)</td>
<td>Sildenafil 20, 40 or 80 mg three times daily</td>
<td>12 weeks</td>
<td>278 treatment-naive patients with IPAH, PAH-CTD or with repaired congenital systemic-to-pulmonary shunts</td>
<td>Change from baseline in 6MWD at week 12. Mean treatment difference +45 m (99% CI 21 to 70) for 20 mg; +46 m (99% CI 20 to 72) for 40 mg; +50 m (99% CI 23 to 77) for 80 mg</td>
<td>Mean PAP, WHO FC, haemodynamics</td>
<td>Headache, flushing, dyspepsia</td>
</tr>
<tr>
<td>Tadalafil in the treatment of pulmonary arterial hypertension (PHIRST-1)</td>
<td>Tadalafil 2.5, 10, 20 or 40 mg once daily</td>
<td>16 weeks</td>
<td>405 treatment-naive or pretreated patients with PAH</td>
<td>Change from baseline in 6MWD at week 16. Mean treatment difference +33 m (95% CI 15 to 50). Endpoint not met in pretreated patients</td>
<td>Mean PAP, PVR, cardiac index, QoL</td>
<td>Headache, myalgia, flushing</td>
</tr>
<tr>
<td>Pulmonary arterial hypertension soluble guanylate cyclase–stimulator trial 1 (PATENT-1)</td>
<td>Riociguat 1.5 mg or 2.5 mg three times daily</td>
<td>12 weeks</td>
<td>443 treatment-naive or pretreated patients with PAH</td>
<td>Change from baseline in 6MWD at week 12. Mean treatment difference +36 m (95% CI 20 to 52)</td>
<td>Haemodynamics, NT-proBNP, WHO FC, TTCW, Borg dyspnoea score</td>
<td>Headache, dizziness, dyspepsia, hypotension, peripheral oedema</td>
</tr>
</tbody>
</table>

6MWD: 6 min walking distance; BNP: B-type natriuretic peptide; IPAH: idiopathic PAH; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NYHA FC: New York Heart Association functional class; PAH: pulmonary arterial hypertension; PAH-CTD, PAH associated with connective tissue disease; PAP: pulmonary arterial pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; QoL: quality of life; TTCW, time to clinical worsening; WHO FC: WHO functional class.
Blockade of endothelin receptors

Endothelin 1 (ET-1) is a potent vasoconstrictor and promoter of pulmonary artery smooth muscle cell proliferation which is upregulated in PAH. There are two ET-1 receptor subtypes: endothelin receptors A (ET_{AR}) and B (ET_{BR}). ET_{BR} is highly expressed in VSMCs and contributes to ET-1-induced contraction and proliferation of VSMCs in PAH. ET_{AR} is predominantly expressed in vascular endothelial cells where activation with ET-1 promotes vasodilation through accelerated production of PGI2 and nitric oxide (NO) and clearance of ET-1 but is also expressed in VSMCs, where it has vasoconstrictive and proliferative actions. ET receptors are also upregulated in PAH. The dual ERAs bosentan and macitentan, and the selective ET_{AR} antagonist ambrisentan bind and block the ET receptors, preventing ET-1-mediated responses.

**Bosentan**

Bosentan is a dual ERA, administered orally. It is approved for the treatment of patients with PAH in WHO FC II–IV in the USA and several other regions, and in patients in WHO FC II–III in Europe. It may be associated with increased levels of liver transaminases; therefore patients are started on a low dose, which is up-titrated to the therapeutic dose as long as liver transaminase levels remain normal. Monthly monitoring of liver transaminases is mandatory for patients taking bosentan. Details of the BREATHE-1 and EARLY studies are given in table 3.

**Ambrisentan**

Ambrisentan is a selective ET_{AR} antagonist with a longer half-life than bosentan (9 h vs 5.4 h, respectively), administered orally. It is approved for the treatment of patients with PAH in WHO FC II and III in the USA, Europe and several other regions. Theoretically, selective ET_{AR} antagonists should be more effective than dual ERAs in that they only target the vasoconstrictive and mitogenic activities of ET-1–ET_{AR}, while preserving the vasodilatory and antimitogenic effect of ET-1–ET_{BR}. Despite its selectivity for ET_{AR}, ambrisentan has not shown greater efficacy in non-comparative monotherapy clinical trials, compared with bosentan. This may be because the distribution of function of ET_{AR} is altered in disease states, and thus dual receptor blockers appear to perform as well as those ERAs with a specific target. Unlike bosentan, ambrisentan was not associated with elevated liver toxicity but peripheral oedema was reported more frequently compared with placebo. Details of the ARIES-1 and ARIES-2 trials are given in table 3, and the ARIES-E extension study is detailed in table 4.

**Macitentan**

Macitentan is a dual receptor ERA, administered orally. It is approved for the treatment of PAH for the long-term treatment of WHO FC II and III patients with PAH in the USA and Europe. Macitentan was not associated with liver toxicity. Decreased haemoglobin levels have been reported more frequently in patients receiving macitentan versus placebo in randomised controlled trials. Details of the SERAPHIN study are given in table 3.

---

**Table 4. Long-term extension studies**

<table>
<thead>
<tr>
<th>Trial name</th>
<th>Number of patients</th>
<th>Primary endpoint</th>
<th>Secondary endpoints</th>
<th>Treatment</th>
<th>Trial design</th>
<th>Safety and tolerability</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIES-E extension study</td>
<td>329 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Ambrisentan</td>
<td>2-year, blinded</td>
<td>After 3 years, 6MWD had increased in 46% of patients, WHO FC was improved or stable in 60% of patients</td>
<td>Headache, dyspepsia, diarrhea, blurred vision, peripheral oedema, headache, upper respiratory tract infection</td>
</tr>
<tr>
<td>AMB-321 (ARIES-E)</td>
<td>329 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Ambrisentan</td>
<td>3-year, open-label, uncontrolled extension study</td>
<td>6MWD improvements were maintained for up to 1 year</td>
<td>Diarrhoea, nausea, vomiting, peripheral oedema</td>
</tr>
<tr>
<td>AMB-320</td>
<td>259 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Ambrisentan</td>
<td>1-year, open-label, uncontrolled extension study</td>
<td>6MWD improvements were maintained for up to 1 year</td>
<td>Headache, diarrhoea, back pain, peripheral oedema, infection</td>
</tr>
<tr>
<td>PHIRST-2</td>
<td>396 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Bosentan</td>
<td>52-week, double-blind, uncontrolled extension study</td>
<td>6MWD, haemodynamics, NT-proBNP, WHO FC, ITCM, Borg dyspnoea score and QoL improvements were maintained for up to 1 year</td>
<td>Headache, diarrhoea, nausea, vomiting, peripheral oedema</td>
</tr>
<tr>
<td>SUPER-2</td>
<td>293 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Sildenafil</td>
<td>1-year, open-label, uncontrolled extension study</td>
<td>6MWD, haemodynamics, NT-proBNP, WHO FC, ITCM, Borg dyspnoea score and QoL improvements were maintained for up to 1 year</td>
<td>Headache, diarrhoea, back pain, peripheral oedema, infection</td>
</tr>
<tr>
<td>PATENT-2</td>
<td>396 patients</td>
<td>Improvements in ARIES-1 score, stabilised WHO FC, low risk of clinical worsening and mortality</td>
<td>Safety and tolerability</td>
<td>Macitentan</td>
<td>1-year, open-label, uncontrolled extension study</td>
<td>6MWD, haemodynamics, NT-proBNP, WHO FC, ITCM, Borg dyspnoea score and QoL improvements were maintained for up to 1 year</td>
<td>Headache, diarrhoea, nausea, vomiting, peripheral oedema</td>
</tr>
</tbody>
</table>

---

Inhibition of phosphodiesterase-5

The PDE superfamily of enzymes inactivates and degrades cyclic guanosine monophosphate (cGMP) and cAMP, important vasoactive mediators that, via activation of cGMP-dependent protein kinase (PKG) and PKA, trigger vasodilation and inhibit proliferation (PKG can also be activated by increasing levels of cAMP). PDE5 is abundantly expressed in the VSMCs of the pulmonary vasculature and is upregulated in PAH in the VSMCs, and in right ventricle (RV) cardiomyocytes.63–66 The upregulation of PDE5 results in increased hydrolysis of cGMP. The PDE5 inhibitors sildenafil and tadalafil occupy the catalytic site on PDE5, blocking the degradation of cGMP.67 PDE5 inhibitors prevent cGMP degradation but are dependent on cGMP synthesis and the presence of NO.68 69 However, there is also evidence to suggest that the beneficial effects of PDE5 inhibition in PH are influenced by natriuretic peptide activity and the presence of natriuretic peptide-derived cGMP.70

Sildenafil

Sildenafil is an oral PDE5 inhibitor approved for the treatment of patients with PAH in WHO FC II–III in Europe and WHO FC II–IV in the USA. The details of SUPER-1 and SUPER-2, the long-term extension are given in tables 3 and 4.

Tadalafil

Tadalafil is an oral PDE5 inhibitor with a longer half-life than sildenafil, allowing once-daily dosing, rather than the three times daily dose that is indicated with sildenafil. It is approved in the USA, Europe and several other countries for the treatment of patients with PAH in WHO FC II–III. Details of the PHIRST-1 study and its long-term extension PHIRST-2 are given in tables 3 and 4.

Stimulation of sGC

sGC is expressed in the VSMCs of the pulmonary vasculature, platelets, RV and other tissues. When bound to NO, sGC catalyses the conversion of GTP to cGMP,71 72 promoting vasodilation and inhibiting smooth muscle proliferation, leucocyte recruitment, inflammation, fibrosis, platelet aggregation and vascular remodelling via several downstream mechanisms.73 The sGC stimulator riociguat is the first member of this novel class of therapeutics.69 73–75

Riociguat

Riociguat is an oral sGC stimulator with a dual mode of action. It sensitises sGC to endogenous NO by stabilising NO–sGC binding. Riociguat also directly stimulates sGC, independently of NO,73 74 resulting in increased generation of cGMP75 76 Currently, riociguat is the only pharmacotherapy to be approved for the treatment of two PH indications, PAH and chronic thromboembolic PH (CTEPH).14–16 Riociguat is approved in the USA, Europe and several other regions for patients with group I PAH in WHO FC II or III; and for the treatment of patients with inoperable CTEPH, or persistent/recurrent PH after pulmonary endarterectomy in WHO FC II or III. Patients receiving riociguat have their dose individually adjusted up to the optimal dose over a period of 8 weeks, according to the patient’s systolic systemic arterial blood pressure and signs or symptoms of hypotension.

Riociguat and PDE5 inhibitors act on separate targets within the NO signalling pathway. Combining them may increase the risk of amplifying their effects, leading to systemic hypotension. Therefore, the use of PDE5 inhibitors in conjunction with riociguat is contraindicated.14–16 77 Rare cases of haemoptysis have been reported with riociguat therapy in patients with PAH and CTEPH. Details of the PATENT-1 study and its long-term extension PATENT-2 are given in tables 3 and 4.

Combination therapy

Combining two or more classes of agent is a strategy that has been used successfully in the treatment of many other cardiovascular conditions such as systemic hypertension and heart failure.17 Combination therapy can be given as first-line treatment or by sequentially adding drugs to a patient’s treatment regimen. The 2013 updated algorithm of PAH treatment from the 5th World Symposium on PH recommends sequential combination therapy, due to the high level of evidence of efficacy, in patients with PAH with an inadequate response to monotherapy, and possible first-line combination therapy in WHO FC III and IV patients with a lower recommendation.17 Several clinical trials have now assessed the effect of combination therapy in patients with PAH, with mixed results (see below). Several recent meta-analyses of the efficacy of combination therapy versus monotherapy, however, conclude that combination therapy can improve clinical outcomes, but has no proven effect on mortality.78–81 However, all acknowledge that more data are required from further studies.

First-line combination therapy

There are few data available on the use of combination therapy as a first-line treatment. The BREATHE-2 study investigated the effect of combined treatment with bosentan and epoprostenol versus epoprostenol and placebo in a small group of 33 patients with severe PAH (WHO FC III and IV) over 16 weeks, but did not demonstrate a significant difference between the two treatments in the primary endpoint of total pulmonary resistance. Three deaths were reported, all in the bosentan arm; however, investigators concluded that they reflected the severity and progressive nature of PAH and were not related to study treatment.

First-line combination therapy with ambrisentan and tadalafil was evaluated in the randomised, multicentre AMBITION study.82–84 This study had a dual placebo design, with one placebo group receiving ambrisentan monotherapy with placebo tadalafil, while the second placebo group received tadalafil monotherapy with placebo ambrisentan. With 610 patients enrolled, and followed up for up to 3.5 years,84 AMBITION was a considerably larger trial than the pioneer BREATHE-2 study. Significant improvements were seen in the composite primary endpoint of morbidity/mortality in the combination group compared with the pooled monotherapy arms, which were driven by differences in hospitalisation. Hierarchical testing of secondary endpoints showed significant improvements in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), proportion of patients with satisfactory clinical response, and 6MWD. No important safety signals were observed. At the time of writing, the results of the AMBITION trial have only been presented in abstract form and have not yet been published.83

Sequential combination therapy

Several studies have evaluated the efficacy of adding a new therapy to a patient’s existing PAH treatment regimen, with variable results (figure 2).

The addition of sildenafil or riociguat to prostanoid treatment has proved successful. The PACES study investigated the addition of sildenafil 80 mg three times daily (four times the
approved dose) to the treatment of 267 patients with PAH already receiving epoprostenol.\textsuperscript{85} After 16 weeks of treatment, improvements were seen in 6MWD, mean pulmonary arterial pressure, cardiac output, time to clinical worsening (TTCW) and quality of life (QoL) compared with placebo. Adverse events (AEs) observed more often with sildenafil treatment were headache and dyspepsia.\textsuperscript{85} PATENT-131 investigated the efficacy and safety of riociguat as combination therapy and monotherapy. Of 443 patients, 222 were receiving ERAs (n=194) or non-intravenous prostanoids (n=28). Overall, after 12 weeks of treatment, 6MWD, PVR, NT-proBNP, WHO FC, TTCW, QoL and Borg dyspnoea score were significantly improved. Riociguat was effective in combination therapy and as monotherapy. The most common AEs that occurred during the study were headache, dyspepsia and peripheral oedema.\textsuperscript{31}

Macitentan has been shown to be effective in patients already receiving either non-intravenous prostanoids or PDE5 inhibitors. The SERAPHIN study\textsuperscript{28} investigated whether long-term treatment with macitentan reduced a combined endpoint of morbidity or mortality in patients with PAH as either combination or monotherapy over 3 years.\textsuperscript{86} Of 742 patients treated, 471 were receiving either PDE5 inhibitors (n=454) or non-intravenous prostanoids (n=40). Overall, there was a significant reduction in the risk of a combined endpoint event in patients receiving macitentan compared with placebo, which was driven by deterioration in PAH. The risk of a combined endpoint event for patients receiving macitentan as monotherapy was lower than for patients receiving macitentan in combination therapy. However, patients receiving combination therapy showed a significant improvement in 6MWD, whereas patients receiving macitentan monotherapy did not. Nasopharyngitis, headache and anaemia were more common in patients receiving macitentan than those receiving placebo.\textsuperscript{28}

The efficacy of adding bosentan to other therapies has not been proven, despite its evaluation in several studies. In the phase IV, event-driven COMPASS-2\textsuperscript{87} study, 334 patients receiving sildenafil for at least 12 weeks were randomised to either placebo or bosentan. The primary endpoint of time to the first morbidity/mortality event (defined as death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or worsening PAH) was not met, with a non-significant observed risk reduction for morbidity/mortality. Improvements were observed in secondary endpoints 6MWD and NT-proBNP. The safety profile was consistent with that of bosentan, with no new signals observed.\textsuperscript{87}

In a study design that was essentially a reversal of COMPASS-2, NCT00323297\textsuperscript{88} investigated the addition of sildenafil to the treatment of 103 patients with PAH already receiving macitentan compared with placebo.

**Figure 2** Combination therapy strategies tested in randomised controlled clinical trials. ERA, endothelin receptor antagonist; PDE5, phosphodiesterase type 5; sGC, soluble guanylate cyclase.
receiving bosentan. The trial did not meet its primary endpoint of a significant increase in 6MWD in patients treated with combined bosentan and sildenafil compared with patients treated with bosentan alone. The most common AEs in the sildenafil group were diarrhoea, headache and peripheral oedema. 88

The addition of riociguat on top of bosentan therapy has been efficacious in PATENT-1. 31 However, the STEP study investigating the addition of inhaled iloprost to bosentan treatment in patients with PAH (n=67) showed a numerically greater 6MWD in the inhaled iloprost plus bosentan group compared with bosentan alone at 12 weeks. While this trend did not reach statistical significance, there were significant improvements in WHO FC, TTCW, mean pulmonary artery pressure and PVR. The most frequently reported AEs in the iloprost group were consistent with the safety profile of prostanoids, and included headache, flushing and jaw pain. 89

The PHIRST study investigated tadalafil as monotherapy or in combination therapy, with bosentan in 405 patients. After 16 weeks, improvement in 6MWD in patients receiving tadalafil as monotherapy was significant, whereas that of patients receiving combination therapy was not. The most common treatment-related AEs reported with tadalafil were headache, myalgia and flushing. 30

COMPASS-3 was a study investigating the benefits of a stepped approach to combination therapy. One hundred treatment-naïve patients started receiving bosentan for 16 weeks. If they failed to achieve a 6MWD ≥380 m by week 16, they were given sildenafil in addition to bosentan. At the end of the trial, 31% of patients had achieved the ≥380 m threshold (16% on monotherapy and 15% on combination therapy). No statistical analysis is available. The most common reported AEs were peripheral oedema, dyspnœa, headache, dizziness, anaemia and abnormal liver function tests. 90

There is some evidence that the delivery route of a drug may influence its efficacy in combination with other drugs. The TRIUMPH study investigated the effect of adding inhaled treprostinil to the therapy regimen of 235 patients with PAH who were receiving bosentan or sildenafil. After 12 weeks, there were significant improvements in 6MWD, QoL and NT-proBNP but not in TTCW or WHO FC. AEs associated with treprostinil treatment were cough, headache and flushing. Conversely, the addition of oral treprostinil to similar background therapy as TRIUMPH was not successful. The FREEDOM-C study investigated the effect of adding oral treprostinil to the regimen of 350 patients receiving ERA and/or PDE5 inhibitors. After 16 weeks, the primary endpoint, improvement in 6MWD, did not reach significance. AEs that resulted in study drug discontinuation included headache, nausea, diarrhoea, vomiting, worsening PH, extremity pain, chest discomfort and myalgia. 91

The background therapy of a patient may also influence the choice of add-on treatment. For patients who are already receiving PDE5 inhibitors, riociguat is contraindicated. The phase II PATENT-PLUS study investigated the safety and clinical effect of riociguat in combination with sildenafil in 18 patients. After 12 weeks, combination therapy showed no favourable effects on exploratory clinical parameters, including haemodynamics and 6MWD. The primary endpoint of the trial, change from baseline in supine systolic blood pressure versus placebo, did not show a difference between riociguat and placebo. There were unfavourable safety signals (high rates of discontinuation due to hypotension and SAEs) with sildenafil plus riociguat in the long-term, single-arm, open-label phase of the study and no evidence of a positive benefit/risk ratio. 77

**CONCLUSIONS**

The pathobiology of PAH is complex, and it is necessary for prescribing clinicians to have a thorough understanding of the mode of action of the drugs available for PAH and of the evidence base of various combinations. The approval of riociguat has introduced a new, fourth class of pharmacotherapy, targeting the NO→Gc→cGMP pathway with a different molecular target to previously approved PDE5 inhibitors. However, comparative studies of the approved classes of therapy are lacking. Although more evidence from trials of various therapies in combination is becoming available, the benefits of many therapy combinations remain inconclusive. The question of sequential versus first-line combination therapy is still under investigation, with further studies warranted. Combination therapy according to patient phenotype will also need to be guided by future studies. Despite the advances made in recent years, PAH remains an incurable disease and as such, there is still an unmet medical need for new therapies, possibly targeting alternative pathways.

**Funding** Editorial assistance, provided by Adelphi Communications Ltd (Bollington, UK), was sponsored by Bayer Pharma AG.

**Competing interests** MH has received consultancy fees from Actelion, Bayer, GSK, Novartis, Pfizer and Aries. He has received speaker fees from Actelion, Bayer, GSK, Novartis and Pfizer. H-AG has received consultancy fees from Actelion, Bayer, Ergonex, Gilead, GSK, Merck, Novartis and Pfizer. He has received speaker fees from Actelion, Bayer, Ergonex, Gilead, GSK, Novartis and Pfizer.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**

Tuder RM, Cool CD, Geraci MW, et al. 
Humbert M, Ghofrani H-A. 
Gryglewski RJ. Prostacyclin among prostanoids.
Wallerstedt SM, Bodelsson M. Endothelium-dependent relaxation by substance P in human isolated omental arteries and veins: relative contribution of prostanoids, nitric oxide, and 2.
Corbin JD, Francis SH. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. 
Wallerstedt SM, Bodelsson M. Endothelin-dependent relaxation by substance P in human isolated omental arteries and veins: relative contribution of prostanoids, nitric oxide, and hyperpolarization. 
Vane J, Corin RE. Prostacyclin: a vascular mediator. 
Mot Pharmacol 2003;64:249–58.
Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. 
Am J Respir Crit Care Med 1999;159:1925–32.
Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? 
Circulation 2002;106:1477–82.
J Am Coll Cardiol 2008;52:1199–205.
McLaughlin VV, Channick RN, Chin KM, et al. Effect of sildenafil on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study, 
J Am Coll Cardiol 2015;65.
Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. 
Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. 
Frumin LR. The pharmacological treatment of pulmonary arterial hypertension. 
Eguchi S, Hirata Y, Marumo F. Endothelin subtype B receptors are coupled to adenylate cytoside via inhibitor B protein in cultured bovine endothelial cells. 
Humbert M, Segal ES, KielYG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. 
Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? 
Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. 
Murray F, Maclean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cAMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. 
Nagendran J, Archer SL, Yki-Jarvinen H. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. 
Corbin JD, Francis SH. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. 
Androl 2003;24:538–41.
Stach JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. 
Circulation 2011;123:2263–73.
Zhao L, Mason NA, Stringer DK, et al. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. 
Arnold WP, Mitral CK, Katsuki S, et al. Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic monophosphate levels in various tissue preparations. 
Stach JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. 


83 Galié N. The AMBITION study: design and results. Eur Respir J 2014;44.


88 Pfizer. Assess the efficacy and safety of sildenafil when added to bosentan in the treatment of pulmonary arterial hypertension. 2014. https://clinicaltrials.gov/ct2/show/study/NCT00323297


The molecular targets of approved treatments for pulmonary arterial hypertension

Marc Humbert and Hossein-Ardeschir Ghofrani

Thorax published online July 28, 2015

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2015/07/28/thoraxjnl-2015-207170

These include:

References
This article cites 80 articles, 27 of which you can access for free at:
http://thorax.bmj.com/content/early/2015/07/28/thoraxjnl-2015-207170#ref-list-1

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (272)
Medicines regulation (22)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/